Clinical Orthopaedics and Related Research

, Volume 466, Issue 3, pp 714–721

Potent Anticoagulants are Associated with a Higher All-Cause Mortality Rate After Hip and Knee Arthroplasty

  • Nigel E. Sharrock
  • Alejandro Gonzalez Della Valle
  • George Go
  • Stephen Lyman
  • Eduardo A. Salvati
Original Article

Abstract

Anticoagulation for thromboprophylaxis after THA and TKA has not been confirmed to diminish all-cause mortality. We determined whether the incidence of all-cause mortality and pulmonary embolism in patients undergoing total joint arthroplasty differs with currently used thromboprophylaxis protocols. We reviewed articles published from 1998 to 2007 that included 6-week or 3-month incidence of all-cause mortality and symptomatic, nonfatal pulmonary embolism. Twenty studies included reported 15,839 patients receiving low-molecular-weight heparin, ximelagatran, fondaparinux, or rivaroxaban (Group A); 7193 receiving regional anesthesia, pneumatic compression, and aspirin (Group B); and 5006 receiving warfarin (Group C). All-cause mortality was higher in Group A than in Group B (0.41% versus 0.19%) and the incidence of clinical nonfatal pulmonary embolus was higher in Group A than in Group B (0.60% versus 0.35%). The incidences of all-cause mortality and nonfatal pulmonary embolism in Group C were similar to those in Group A (0.4 and 0.52, respectively). Clinical pulmonary embolus occurs despite the use of anticoagulants. Group A anticoagulants were associated with the highest all-cause mortality of the three modalities studied.

Level of Evidence: Level III, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.

References

  1. 1.
    Amin AK, Patton JT, Cook RE, Brenkel IJ. Does obesity influence the clinical outcome at five years following total knee replacement for osteoarthritis? J Bone Joint Surg Br. 2006;88:335–340.PubMedCrossRefGoogle Scholar
  2. 2.
    Amstutz HC, Dorey FJ. Are recommendations for the routine use of pharmacological thromboprophylaxis in total hip arthroplasty justified? J Bone Joint Surg Br. 2000;82:473–474.PubMedCrossRefGoogle Scholar
  3. 3.
    Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305–1310.PubMedCrossRefGoogle Scholar
  4. 4.
    Berend ME, Ritter MA, Harty LD, Davis KE, Keating EM, Meding JB, Thong AE. Simultaneous bilateral versus unilateral total hip arthroplasty an outcomes analysis. J Arthroplasty. 2005;20:421–426.PubMedCrossRefGoogle Scholar
  5. 5.
    Callaghan JJ, Dorr LD, Engh GA, Hanssen AD, Healy WL, Lachiewicz PF, Lonner JH, Lotke PA, Ranawat CS, Ritter MA, Salvati EA, Sculco TP, Thornhill TS. Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians: are they appropriate for orthopaedic surgery? J Arthroplasty. 2005;20:273–274.PubMedCrossRefGoogle Scholar
  6. 6.
    Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. J Thromb Haemost. 2003;1:2119–2130.PubMedCrossRefGoogle Scholar
  7. 7.
    Colwell CW Jr, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, McElhattan J, Roth AW, Francis CW. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005;87:2169–2177.PubMedCrossRefGoogle Scholar
  8. 8.
    Colwell CW Jr, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 1999;81:932–940.PubMedCrossRefGoogle Scholar
  9. 9.
    Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, Landon GC, Jove M. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001;83:336–345.PubMedGoogle Scholar
  10. 10.
    Coventry MB, Beckenbaugh RD, Nolan DR, Ilstrup DM. 2,012 total hip arthroplasties: a study of postoperative course and early complications. J Bone Joint Surg Am. 1974;56:273–284.PubMedGoogle Scholar
  11. 11.
    DiGiovanni CW, Restrepo A, Della Valle AG, Sharrock NE, McCabe JP, Sculco TP, Pellicci PM, Salvati EA. The safety and efficacy of intraoperative heparin in total hip arthroplasty. Clin Orthop Relat Res. 2000;379:178–185.PubMedCrossRefGoogle Scholar
  12. 12.
    Dorr LD, Gendelman V, Maheshwari A, Boutary M, Wan Z, Long WT. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg Am. 2007;89:2648–2657.PubMedCrossRefGoogle Scholar
  13. 13.
    Ellis MH, Hadari R, Tchuvrero N, Shapira S, Kovlenko I, Kozmiakova M, Zissin R, Elis A. Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice. Clin Appl Thromb Hemost. 2006;12:199–204.PubMedCrossRefGoogle Scholar
  14. 14.
    Enyart JJ, Jones RJ. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. Ann Pharmacother. 2005;39:1002–1007.PubMedCrossRefGoogle Scholar
  15. 15.
    Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P. Oral, direct Factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121–128.PubMedCrossRefGoogle Scholar
  16. 16.
    Fender D, Harper WM, Thompson JR, Gregg PJ. Mortality and fatal pulmonary embolism after primary total hip replacement: results from a regional hip register. J Bone Joint Surg Br. 1997;79:896–899.PubMedCrossRefGoogle Scholar
  17. 17.
    Francis CW, Pellegrini VD Jr, Totterman S, Boyd AD Jr, Marder VJ, Liebert KM, Stulberg BN, Ayers DC, Rosenberg A, Kessler C, Johanson NA. Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg Am. 1997;79:1365–1372.PubMedGoogle Scholar
  18. 18.
    Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82:929–938.PubMedGoogle Scholar
  19. 19.
    Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):338S–400S.PubMedCrossRefGoogle Scholar
  20. 20.
    Gillespie W, Murray D, Gregg PJ, Warwick D. Risks and benefits of prophylaxis against venous thromboembolism in orthopaedic surgery. J Bone Joint Surg Br. 2000;82:475–479.PubMedCrossRefGoogle Scholar
  21. 21.
    Gonzalez Della Valle A, Serota A, Go G, Sorriaux G, Sculco TP, Sharrock NE, Salvati EA. Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty. Clin Orthop Relat Res. 2006;444:146–153.PubMedCrossRefGoogle Scholar
  22. 22.
    Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132:853–861.PubMedGoogle Scholar
  23. 23.
    Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med. 2000;160:2199–2207.PubMedCrossRefGoogle Scholar
  24. 24.
    Huo MH, Salvati EA, Sharrock NE, Brien WW, Sculco TP, Pellici PM, Mineo R, Go G. Intraoperative heparin thromboembolic prophylaxis in primary total hip arthroplasty: a prospective, randomized, controlled, clinical trial. Clin Orthop Relat Res. 1992;274:35–46.PubMedGoogle Scholar
  25. 25.
    Huo MH, Salvati EA, Sharrock NE, Pellici PM, Sculco TP, Go G, Mineo R, Brien WW. Intraoperative adjusted-dose heparin thromboembolic prophylaxis in primary total hip arthroplasty. Clin Orthop Relat Res. 1992;277:188–196.PubMedGoogle Scholar
  26. 26.
    Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994;271:1780–1785.PubMedCrossRefGoogle Scholar
  27. 27.
    Johnson R, Green JR, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop Relat Res. 1977;127:123–132.PubMedGoogle Scholar
  28. 28.
    Katz JN, Barrett J, Mahomed NN, Baron JA, Wright RJ, Losina E. Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am. 2004;86:1909–1916.PubMedCrossRefGoogle Scholar
  29. 29.
    Katz JN, Losina E, Barrett J, Phillips CB, Mahomed NN, Lew RA, Guadagnoli E, Harris WH, Poss R, Baron JA. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States Medicare population. J Bone Joint Surg Am. 2001;83:1622–1629.PubMedCrossRefGoogle Scholar
  30. 30.
    Kessler DP, Summerton N, Graham JR. Effects of the medical liability system in Australia, the UK, and the USA. Lancet. 2006;368:240–246.PubMedCrossRefGoogle Scholar
  31. 31.
    Lachiewicz PF, Kelley SS, Haden LR. Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty: a prospective, randomised study. J Bone Joint Surg Br. 2004;86:1137–1141.PubMedCrossRefGoogle Scholar
  32. 32.
    Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002;359:1715–1720.PubMedCrossRefGoogle Scholar
  33. 33.
    Leali A, Fetto J, Moroz A. Prevention of thromboembolic disease after non-cemented hip arthroplasty: a multimodal approach. Acta Orthop Belg. 2002;68:128–134.PubMedGoogle Scholar
  34. 34.
    Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med. 1998;158:873–878.PubMedCrossRefGoogle Scholar
  35. 35.
    Lie SA, Engesaeter LB, Havelin LI, Furnes O, Vollset SE. Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand. 2002;73:392–399.PubMedCrossRefGoogle Scholar
  36. 36.
    Lieberman JR, Wollaeger J, Dorey F, Thomas BJ, Kilgus DJ, Grecula MJ, Finerman GA, Amstutz HC. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am. 1997;79:319–325.PubMedGoogle Scholar
  37. 37.
    Lindahl TL, Lundahl TH, Nilsson L, Andersson CA. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee: a prospective study. Thromb Haemost. 1999;81:18–21.PubMedGoogle Scholar
  38. 38.
    Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res. 2006;452:175–180.PubMedCrossRefGoogle Scholar
  39. 39.
    Murray DW, Britton AR, Bulstrode CJ. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br. 1996;78:863–870.PubMedCrossRefGoogle Scholar
  40. 40.
    Nishiguchi M, Takamura N, Abe Y, Kono M, Shindo H, Aoyagi K. Pilot study on the use of tourniquet: a risk factor for pulmonary thromboembolism after total knee arthroplasty? Thromb Res. 2005;115:271–276.PubMedCrossRefGoogle Scholar
  41. 41.
    Pitto RP, Hamer H, Heiss-Dunlop W, Kuehle J. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. J Bone Joint Surg Br. 2004;86:639–642.PubMedCrossRefGoogle Scholar
  42. 42.
    Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, Beau B. Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999;81:22–25.PubMedGoogle Scholar
  43. 43.
    Prentice CR. Thromboprophylaxis: which treatment for which patient? J Bone Joint Surg Br. 2000;82:483–485.PubMedCrossRefGoogle Scholar
  44. 44.
    Prins MH, Hirsh J. A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following total hip surgery: a critical review. Thromb Haemost. 1990;64:497–500.PubMedGoogle Scholar
  45. 45.
    Ragucci MV, Leali A, Moroz A, Fetto J. Comprehensive deep venous thrombosis prevention strategy after total-knee arthroplasty. Am J Phys Med Rehabil. 2003;82:164–168.PubMedCrossRefGoogle Scholar
  46. 46.
    Rodgers A, Walker N, Schug S, McKee A, Kehlet H, van Zundert A, Sage D, Futter M, Saville G, Clark T, MacMahon S. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ. 2000;321:1493–1497.PubMedCrossRefGoogle Scholar
  47. 47.
    Rothwell PM. Observational comparisons of different clinical services. Lancet. 2007;369:254–255.PubMedCrossRefGoogle Scholar
  48. 48.
    Ryan MG, Westrich GH, Potter HG, Sharrock N, Maun LM, Macaulay W, Katkin P, Sculco TP, Salvati EA. Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. J Bone Joint Surg Am. 2002;84:1998–2004.PubMedGoogle Scholar
  49. 49.
    Sachs RA, Smith JH, Kuney M, Paxton L. Does anticoagulation do more harm than good? A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty. J Arthroplasty. 2003;18:389–395.PubMedCrossRefGoogle Scholar
  50. 50.
    Salvati EA, Gonzalez Della Valle A. Thromboembolism following total hip replacement. J Long Term Eff Med Implants. 2003;13:325–340.PubMedCrossRefGoogle Scholar
  51. 51.
    Salvati EA, Pellegrini VD Jr, Sharrock NE, Lotke PA, Murray DW, Potter H, Westrich GH. Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg Am. 2000;82:252–270.PubMedGoogle Scholar
  52. 52.
    Salvati EA, Sharrock N, Gonzalez Della Valle A. Current concepts on the pathogenesis, diagnosis and multimodal prophylaxis of thromboembolic disease after total hip arthroplasty. Minerva Ortop Traumatol. 2003;54:381–401.Google Scholar
  53. 53.
    Salvati EA, Sharrock NE, Westrich G, Potter HG, Valle AG, Sculco TP. The 2007 ABJS Nicolas Andry Award: three decades of clinical, basic, and applied research on thromboembolic disease after THA: rationale and clinical results of a multimodal prophylaxis protocol. Clin Orthop Relat Res. 2007;459:246–254.PubMedCrossRefGoogle Scholar
  54. 54.
    Samama CM, Vray M, Barre J, Fiessinger JN, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med. 2002;162:2191–2196.PubMedCrossRefGoogle Scholar
  55. 55.
    Shaieb MD, Watson BN, Atkinson RE. Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis. J Arthroplasty. 1999;14:432–438.PubMedCrossRefGoogle Scholar
  56. 56.
    Sharrock NE, Go G, Harpel PC, Ranawat CS, Sculco TP, Salvati EA. Thrombogenesis during total hip replacement. Clin Orthop Relat Res. 1995;319:16–27.PubMedGoogle Scholar
  57. 57.
    Tarity TD, Herz AL, Parvizi J, Rothman RH. Ninety-day mortality after hip arthroplasty: a comparison between unilateral and simultaneous bilateral procedures. J Arthroplasty. 2006;21(6 suppl 2):60–64.PubMedCrossRefGoogle Scholar
  58. 58.
    Thomas DP. Whither thromboprophylaxis after total hip replacement? J Bone Joint Surg Br. 2000;82:469–472.PubMedCrossRefGoogle Scholar
  59. 59.
    Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359:1721–1726.PubMedCrossRefGoogle Scholar
  60. 60.
    Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M. BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3:2479–2486.PubMedCrossRefGoogle Scholar
  61. 61.
    Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement: a prospective, randomized trial. J Bone Joint Surg Am. 1998;80:1158–1166.PubMedGoogle Scholar

Copyright information

© The Association of Bone and Joint Surgeons 2008

Authors and Affiliations

  • Nigel E. Sharrock
    • 1
  • Alejandro Gonzalez Della Valle
    • 2
  • George Go
    • 1
  • Stephen Lyman
    • 3
  • Eduardo A. Salvati
    • 2
  1. 1.Department of AnesthesiologyHospital for Special SurgeryNew YorkUSA
  2. 2.Department of Orthopaedic SurgeryHospital for Special SurgeryNew YorkUSA
  3. 3.Foster Center for Clinical Outcome ResearchHospital for Special SurgeryNew YorkUSA

Personalised recommendations